Toniv,
See my post from a day or two ago. In the patent, all Pfizer has done is test RVX-208 and a battery of other BET inhibitors in human cells. No Friedreich’s Ataxia patients have been treated with any BET inhibitor in any clinical trial yet. To study a Friedreich’s Ataxia indication, I think the interested party would need to file a new IND as well as start in Phase I trials. To the best of my knowledge neither has happened yet.
BDAZ